AstraZeneca Closes Acquisition of Amolyt Pharma

Core Insights - Amolyt Pharma has been acquired by AstraZeneca for a total consideration of up to $1.05 billion, enhancing AstraZeneca's rare disease pipeline and expanding its bone metabolism franchise [3]. Group 1: Acquisition Details - The acquisition includes an upfront payment of$800 million at deal closing, with an additional contingent payment of $250 million based on achieving a specified regulatory milestone [3]. - The acquisition is expected to bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline, particularly with the addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide [2]. Group 2: Product and Pipeline Expansion - Enebo paratide (AZP-3601) is designed to address hypoparathyroidism, a condition caused by a deficiency in parathyroid hormone (PTH) production, leading to significant calcium and phosphate dysregulation [2]. - Amolyt Pharma's portfolio also includes AZP-3813, a peptide growth hormone receptor antagonist aimed at treating acromegaly, indicating a focus on rare endocrine diseases [4].